SUCCINIC ACID MONO-(13-METHYL-3-OXO-2,3,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-17-YL) ESTER

DB08308ExperimentalSmall molecule

SUCCINIC ACID MONO-(13-METHYL-3-OXO-2,3,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-17-YL) ESTER: Overview.

Formula / weight: C₂₂H₃₀O₅ · 374.4706 g/mol (avg)

Resolves to

Compound

PubChem5289054

Structure

InChIKeyIRQUJNVGEAJGSD-KIEDKLRZSA-NSMILES[H][C@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4([H])[C@@]3([H])CC[C@]12C)OC(=O)CCC(O)=O

Targets

P00947ksi

What you can answer from here — as of April 02, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with SUCCINIC ACID MONO-(13-METHYL-3-OXO-2,3,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-17-YL) ESTER, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account